Cetuximab, Capecitabine, Oxaliplatin and Bevacizumab in Advanced Colorectal Cancer
Status:
Completed
Trial end date:
2009-12-01
Target enrollment:
Participant gender:
Summary
This is a study to assess the efficacy and safety of the addition of cetuximab to the
combined regimen of capecitabine, oxaliplatin and bevacizumab in patients with previously
untreated advanced colorectal carcinoma. It is an open, comparative study, comparing the
effects of capecitabine, oxaliplatin and bevacizumab to those of the same regimen plus
cetuximab.
Seven hundred fifty patients will be included. Treatment will continue until disease
progression or serious toxicity and follow up will continue until death. It is anticipated
that the addition of cetuximab will lead to an increase in progression free survival.
Phase:
Phase 3
Details
Lead Sponsor:
Dutch Colorectal Cancer Group
Collaborators:
Immunicon Koningin Wilhelmina Fonds Roche Pharma AG Sanofi